KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Current Deferred Revenue (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Current Deferred Revenue readings, the most recent being $2.9 billion for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue rose 2.16% to $2.9 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $2.9 billion, a 2.16% increase, with the full-year FY2025 number at $2.7 billion, down 4.98% from a year prior.
  • Current Deferred Revenue hit $2.9 billion in Q1 2026 for Thermo Fisher Scientific, up from $2.7 billion in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.9 billion in Q1 2026 to a low of $2.5 billion in Q3 2023.
  • Median Current Deferred Revenue over the past 5 years was $2.7 billion (2023), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Current Deferred Revenue: surged 105.66% in 2022 and later decreased 7.28% in 2023.
  • Thermo Fisher Scientific's Current Deferred Revenue stood at $2.6 billion in 2022, then rose by 3.38% to $2.7 billion in 2023, then rose by 6.06% to $2.9 billion in 2024, then dropped by 4.98% to $2.7 billion in 2025, then rose by 8.04% to $2.9 billion in 2026.
  • The last three reported values for Current Deferred Revenue were $2.9 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.9 billion (Q3 2025) per Business Quant data.